Akoya Biosciences, Inc. (NASDAQ:AKYA) Shares Acquired by JPMorgan Chase & Co.

JPMorgan Chase & Co. increased its holdings in shares of Akoya Biosciences, Inc. (NASDAQ:AKYA) by 295.4% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 48,313 shares of the company’s stock after purchasing an additional 36,093 shares during the quarter. JPMorgan Chase & Co. owned 0.10% of Akoya Biosciences worth $111,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Intech Investment Management LLC acquired a new position in shares of Akoya Biosciences during the 4th quarter valued at $27,000. SVB Wealth LLC acquired a new position in shares of Akoya Biosciences during the fourth quarter worth about $1,180,000. SG Americas Securities LLC purchased a new stake in shares of Akoya Biosciences in the fourth quarter worth about $28,000. Finally, Barclays PLC grew its stake in shares of Akoya Biosciences by 320.9% in the third quarter. Barclays PLC now owns 39,472 shares of the company’s stock valued at $107,000 after buying an additional 30,095 shares in the last quarter. Hedge funds and other institutional investors own 79.42% of the company’s stock.

Akoya Biosciences Trading Up 2.5 %

AKYA opened at $1.25 on Tuesday. Akoya Biosciences, Inc. has a 12-month low of $1.01 and a 12-month high of $4.65. The company has a debt-to-equity ratio of 5.62, a current ratio of 2.75 and a quick ratio of 1.85. The stock has a market capitalization of $62.34 million, a PE ratio of -1.06 and a beta of 1.34. The firm’s fifty day moving average price is $1.37 and its 200 day moving average price is $2.14.

Akoya Biosciences (NASDAQ:AKYA) last issued its quarterly earnings results on Monday, March 17th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.02). The company had revenue of $21.34 million for the quarter, compared to the consensus estimate of $21.34 million. Akoya Biosciences had a negative return on equity of 162.99% and a negative net margin of 66.77%. As a group, research analysts expect that Akoya Biosciences, Inc. will post -0.96 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on AKYA. Canaccord Genuity Group decreased their price target on Akoya Biosciences from $3.50 to $1.80 and set a “hold” rating for the company in a report on Tuesday, April 29th. Stephens restated an “equal weight” rating and issued a $1.80 target price (down from $3.50) on shares of Akoya Biosciences in a research note on Tuesday, March 25th. Finally, Piper Sandler dropped their price target on shares of Akoya Biosciences from $2.40 to $1.65 and set a “neutral” rating on the stock in a research note on Monday, April 14th. Seven research analysts have rated the stock with a hold rating, According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $3.21.

About Akoya Biosciences

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.